Nature-inspired IL-1 targeted therapy to treat chronic inflammatory diseases
Mol Ther. 2025 Sep 10:S1525-0016(25)00736-1. doi: 10.1016/j.ymthe.2025.09.008. Online ahead of print. ABSTRACT The interleukin (IL)-1 pathway is a key mediator […]
Mol Ther. 2025 Sep 10:S1525-0016(25)00736-1. doi: 10.1016/j.ymthe.2025.09.008. Online ahead of print. ABSTRACT The interleukin (IL)-1 pathway is a key mediator […]
JAMA Otolaryngol Head Neck Surg. 2025 Sep 11. doi: 10.1001/jamaoto.2025.2816. Online ahead of print. ABSTRACT IMPORTANCE: The oral microbiome plays
Allergy. 2025 Sep 10. doi: 10.1111/all.70037. Online ahead of print. ABSTRACT Hypersensitivity reactions to quinolones (QHRs) have been increasing in
Arthritis Care Res (Hoboken). 2025 Sep 11. doi: 10.1002/acr.25645. Online ahead of print. NO ABSTRACT PMID:40931847 | DOI:10.1002/acr.25645
Arthritis Rheumatol. 2025 Sep 11. doi: 10.1002/art.43374. Online ahead of print. NO ABSTRACT PMID:40931855 | DOI:10.1002/art.43374
Haematologica. 2025 Sep 11. doi: 10.3324/haematol.2025.288147. Online ahead of print. ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative
Arthritis Rheumatol. 2025 Sep 11. doi: 10.1002/art.43378. Online ahead of print. NO ABSTRACT PMID:40931875 | DOI:10.1002/art.43378
Arthritis Rheumatol. 2025 Sep 11. doi: 10.1002/art.43381. Online ahead of print. NO ABSTRACT PMID:40931885 | DOI:10.1002/art.43381
Arthritis Rheumatol. 2025 Sep 11. doi: 10.1002/art.43377. Online ahead of print. ABSTRACT OBJECTIVE: To evaluate the clinical characteristics, social deprivation,
Immunol Med. 2025 Sep 11:1-8. doi: 10.1080/25785826.2025.2557038. Online ahead of print. ABSTRACT OBJECTIVE: We compared the drug retention rate of
BMC Rheumatol. 2025 Sep 10;9(1):104. doi: 10.1186/s41927-025-00567-y. NO ABSTRACT PMID:40931328 | DOI:10.1186/s41927-025-00567-y
Clin Rheumatol. 2025 Sep 10. doi: 10.1007/s10067-025-07684-6. Online ahead of print. ABSTRACT OBJECTIVES: IgG4-related disease (IgG4-RD) can affect multiple organ
Clin Rheumatol. 2025 Sep 10. doi: 10.1007/s10067-025-07685-5. Online ahead of print. NO ABSTRACT PMID:40931288 | DOI:10.1007/s10067-025-07685-5
Nature. 2025 Sep 10. doi: 10.1038/s41586-025-09513-x. Online ahead of print. ABSTRACT Monogenic lupus offers valuable insights into the underlying mechanisms
Cell Mol Immunol. 2025 Sep 10. doi: 10.1038/s41423-025-01346-y. Online ahead of print. ABSTRACT Type I interferon (IFN-I) is highly prevalent
Nat Rev Immunol. 2025 Sep 10. doi: 10.1038/s41577-025-01214-w. Online ahead of print. ABSTRACT Actin cytoskeleton remodelling drives the migration of
Br J Haematol. 2025 Sep 10. doi: 10.1111/bjh.70148. Online ahead of print. ABSTRACT Mastocytosis is categorized into cutaneous mastocytosis (CM),
Lancet Digit Health. 2025 Sep 9:100896. doi: 10.1016/j.landig.2025.100896. Online ahead of print. ABSTRACT BACKGROUND: New-onset atrial fibrillation, a condition associated
J Atheroscler Thromb. 2025 Sep 9. doi: 10.5551/jat.65577. Online ahead of print. ABSTRACT AIMS: In-stent restenosis (ISR) is a significant
BMJ. 2025 Sep 10;390:r1883. doi: 10.1136/bmj.r1883. NO ABSTRACT PMID:40930797 | DOI:10.1136/bmj.r1883
BMJ Open. 2025 Sep 9;15(9):e097802. doi: 10.1136/bmjopen-2024-097802. ABSTRACT INTRODUCTION: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B)
J Atheroscler Thromb. 2025 Sep 11. doi: 10.5551/jat.65781. Online ahead of print. ABSTRACT A 79-year-old Chinese man was referred for
Bone Jt Open. 2025 Sep 11;6(9):1090-1100. doi: 10.1302/2633-1462.69.BJO-2024-0258.R1. ABSTRACT AIMS: We sought to explore staff experience of a paediatric randomized
Mech Ageing Dev. 2025 Sep 8:112112. doi: 10.1016/j.mad.2025.112112. Online ahead of print. ABSTRACT Age-related skeletal muscle decline is a major
Pediatr Exerc Sci. 2025 Sep 10:1-8. doi: 10.1123/pes.2024-0122. Online ahead of print. ABSTRACT BACKGROUND: Juvenile idiopathic arthritis is an autoimmune
Am J Public Health. 2025 Oct;115(10):1572-1574. doi: 10.2105/AJPH.2025.308181. NO ABSTRACT PMID:40929662 | DOI:10.2105/AJPH.2025.308181
Mol Pharm. 2025 Sep 10. doi: 10.1021/acs.molpharmaceut.5c01291. Online ahead of print. NO ABSTRACT PMID:40929712 | DOI:10.1021/acs.molpharmaceut.5c01291